HighTower Advisors
NBIX icon

HighTower Advisors’s Neurocrine Biosciences NBIX Stock Holding History

HighTower Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$2K – 2467
2019
Q1 		$2K Buy
+300
New +$25.1K ﹤0.01% 2253

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's NBIX Position: Q1 2026 in Review

HighTower Advisors reduced its Neurocrine Biosciences (NBIX) stake by 8.7% in Q1 2026, selling an estimated $142K and leaving 11,198 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

HighTower Advisors first reported a position in NBIX in Q4 2017 and has held it in 34 quarters since. The position peaked at $4.07M in Q2 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • HighTower Advisors held 11,198 shares of Neurocrine Biosciences worth $1.48M as of Q1 2026.
  • HighTower Advisors sold 1,073 Neurocrine Biosciences shares in Q1 2026, an estimated $142K.
  • Neurocrine Biosciences made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #1912 holding.
  • HighTower Advisors first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 34 quarters since.
  • HighTower Advisors's Neurocrine Biosciences position peaked at $4.07M in Q2 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.